Knowledge Library

Osimertinib-Resistant Cell Lines and Models

Despite the robust clinical activity exerted by osimertinib, a majority of patients eventually exhibit disease progression while receiving this drug.  Resistance to osimertinib includes both on-target and off-target mechanisms.  With the use of osimertinib for advanced EGFR-mutant NSCLC increasing, the development of targeted therapies toward osimertinib resistance represents an unmet medical need.  To support research …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Lead Optimization, Oncology, Tumor Models

VIEW

Enhertu-Induced Resistant Tumor Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Antibody Drug Conjugate, Oncology, Tumor Models

VIEW

OncoWuXi Express: In vitro and in vivo evaluation of an mRNA-encoded bispecific antibody (EpCAM/CD3)

Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration.  However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >

Resource Type: Article, Blog, Case Study
Resource Topic: Antibodies, Cell-based Assays, Oncology, Tumor Models

VIEW

Metastasis-Related In Vitro Assays and Xenograft Models

Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis.  To support research in this field, WuXi AppTec offers in vitro transwell migration and invasion assays using multiple cell types for assessing cell migratory behavior.  In addition, our in vivo metastasis panel includes a broad range of brain, bone, and liver xenograft models covering …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Cell-based Assays, Oncology, Tumor Models

VIEW

Oncolytic Virus Platform

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity.  WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Biochemical Assays, Cell-based Assays, Oncology, Oncolytic Viruses, Safety and Early Toxicity, Tumor Models

VIEW

Evaluation Platform for Bispecific Antibodies

WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs).  Our comprehensive platform includes cell line selection and target expression, assessment of binding affinity (SPR, flow cytometry), in vitro activity testing (T cell activation, cytokine release, cytotoxicity), and evaluation of in vivo efficacy (using HSC and PBMC …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Cell-based Assays, Oncology, Tumor Models

VIEW

Enzalutamide-resistant LNCaP ARF877L Mutation KI model

We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics.  An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model. Check out our …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Oncology, Tumor Models

VIEW

Tumor Cell Panel | Screening Services

Comprehensive cell line screening assays integrated with downstream pharmacological services Cell panel  of 600+ human cancer cell lines for single agent or combinatory drug screening, covering 30+ cancer types 100+ mouse cell lines, across 20+ cancer types 95 PDX-derived cell lines 320+ CDX models, ready for use 1,400+ PDX models, for primary tumor cell line …Read More >

Resource Type: Brochure
Resource Topic: Oncology, Tumor Models

VIEW

Orthotopic and Metastasis Syngeneic Models

Our comprehensive panel of orthotopic and metastasis syngeneic models includes: 17 orthotopic/disseminated models covering 10 cancer types; Organ-based orthotopic models of solid tumor cell lines; IV injection disseminated models of hematopoietic cancer cell lines; 13 experimental metastasis models covering 7 cancer types

Resource Type: Latest Science, Presentation
Resource Topic: Lead Optimization, Oncology, Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!